142 related articles for article (PubMed ID: 25056363)
1. Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons.
Keck JW; Bulkow LR; Raczniak GA; Negus SE; Zanis CL; Bruce MG; Spradling PR; Teshale EH; McMahon BJ
Clin Vaccine Immunol; 2014 Sep; 21(9):1339-42. PubMed ID: 25056363
[TBL] [Abstract][Full Text] [Related]
2. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
Bruce MG; Bruden D; Hurlburt D; Zanis C; Thompson G; Rea L; Toomey M; Townshend-Bulson L; Rudolph K; Bulkow L; Spradling PR; Baum R; Hennessy T; McMahon BJ
J Infect Dis; 2016 Jul; 214(1):16-22. PubMed ID: 26802139
[TBL] [Abstract][Full Text] [Related]
3. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
[TBL] [Abstract][Full Text] [Related]
4. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination.
Zhao YL; Han BH; Zhang XJ; Pan LL; Zhou HS; Gao Z; Hao ZY; Wu ZW; Ma TL; Wang F; Li Q; Bi SL; Ma JC
BMC Infect Dis; 2019 May; 19(1):482. PubMed ID: 31146699
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for anti-HBs status after 1 booster dose of hepatitis B vaccine.
Lu IC; Jean MC; Lin CW; Chen WH; Perng DS; Lin CW; Chuang HY
Medicine (Baltimore); 2016 Sep; 95(39):e5023. PubMed ID: 27684874
[TBL] [Abstract][Full Text] [Related]
6. The Serum Anti-HBs Level Among Children Who Received Routine Hepatitis B Vaccination During Infancy in Mianyang City, China: A Cross-Sectional Study.
He F; Ma YJ; Zhou TY; Duan JC; Wang JF; Ji YL; Li H; Zhang JY; Tang H
Viral Immunol; 2016; 29(1):40-8. PubMed ID: 26565951
[TBL] [Abstract][Full Text] [Related]
7. Implementation of hepatitis B vaccine in high-risk young adults with waning immunity.
Posuwan N; Vorayingyong A; Jaroonvanichkul V; Wasitthankasem R; Wanlapakorn N; Vongpunsawad S; Poovorawan Y
PLoS One; 2018; 13(8):e0202637. PubMed ID: 30125298
[TBL] [Abstract][Full Text] [Related]
8. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China.
Wang ZZ; Gao YH; Lu W; Jin CD; Zeng Y; Yan L; Ding F; Li T; Liu XE; Zhuang H
Hum Vaccin Immunother; 2017 Apr; 13(4):909-915. PubMed ID: 27874311
[TBL] [Abstract][Full Text] [Related]
9. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study.
Bialek SR; Bower WA; Novak R; Helgenberger L; Auerbach SB; Williams IT; Bell BP
Pediatr Infect Dis J; 2008 Oct; 27(10):881-5. PubMed ID: 18756185
[TBL] [Abstract][Full Text] [Related]
10. Persistence of hepatitis B surface antibody and immune memory to hepatitis B vaccine among medical college students in Madinah.
Mahallawi W
Ann Saudi Med; 2018; 38(6):413-419. PubMed ID: 30531175
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.
Zanetti AR; Romanò L; Giambi C; Pavan A; Carnelli V; Baitelli G; Malchiodi G; Valerio E; Barale A; Marchisio MA; Montù D; Tozzi AE; D'Ancona F;
Lancet Infect Dis; 2010 Nov; 10(11):755-61. PubMed ID: 20884297
[TBL] [Abstract][Full Text] [Related]
12. Response to booster doses of hepatitis B vaccine among young adults who had received neonatal vaccination.
Chan PK; Ngai KL; Lao TT; Wong MC; Cheung T; Yeung AC; Chan MC; Luk SW
PLoS One; 2014; 9(9):e107163. PubMed ID: 25198289
[TBL] [Abstract][Full Text] [Related]
13. The positive rates of hepatitis B surface antibody in youth after booster vaccination: a 4-year follow-up study with large sample.
Zhu X; Wang J; Wang M; Du LY; Ji YL; Zhang X; Tang H
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34151935
[TBL] [Abstract][Full Text] [Related]
14. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines.
Giambi C; Bella A; Barale A; Montù D; Marchisio M; Oddone M; Zito S; Rapicetta M; Chionne P; Madonna E; Ciofi degli Atti ML
BMC Infect Dis; 2008 Jul; 8():100. PubMed ID: 18662386
[TBL] [Abstract][Full Text] [Related]
15. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
Zanetti AR; Mariano A; Romanò L; D'Amelio R; Chironna M; Coppola RC; Cuccia M; Mangione R; Marrone F; Negrone FS; Parlato A; Zamparo E; Zotti C; Stroffolini T; Mele A;
Lancet; 2005 Oct 15-21; 366(9494):1379-84. PubMed ID: 16226616
[TBL] [Abstract][Full Text] [Related]
16. Impact of maternal carrier status on immunologic markers for protection after hepatitis B vaccination in infancy: a meta-analysis.
Schönberger K; Riedel C; Rückinger S; Mansmann U; Jilg W; von Kries R
Vaccine; 2012 Sep; 30(44):6314-26. PubMed ID: 22885275
[TBL] [Abstract][Full Text] [Related]
17. Immune memory and immune response in children from Bulgaria 5-15 years after primary hepatitis B vaccination.
Teoharov P; Kevorkyan A; Petrova N; Baltadzhiev I; Van Damme P
Pediatr Infect Dis J; 2013 Jan; 32(1):51-3. PubMed ID: 22914584
[TBL] [Abstract][Full Text] [Related]
18. The effects of booster vaccination of hepatitis B vaccine on anti-HBV surface antigen negative children 11-15 years after primary vaccination.
Yao J; Ren J; Shen L; Chen Y; Liang X; Cui F; Li Q; Jiang Z; Wang F
Hum Vaccin; 2011 Oct; 7(10):1055-9. PubMed ID: 21989290
[TBL] [Abstract][Full Text] [Related]
19. Persistence of protection to hepatitis B vaccine and response to booster dose among children and adolescents in Dakahleya- Egypt.
Salama II; Sami SM; Salama SI; Foud WA; Abdel Hamid AT; Said ZN
Egypt J Immunol; 2014; 21(1):13-26. PubMed ID: 25204041
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
